Michael J. Farrell is the CEO of ResMed Inc., a healthcare company focused on developing innovative solutions for people with sleep apnea and chronic obstructive pulmonary disease. Since taking the helm in 2019, he has guided the company through significant...

Michael J. Farrell is the CEO of ResMed Inc., a healthcare company focused on developing innovative solutions for people with sleep apnea and chronic obstructive pulmonary disease. Since taking the helm in 2019, he has guided the company through significant growth and transformation. In January 2023, he was appointed as the chair of the board of directors, making him a key figure in both leadership roles. Michael's compensation reflects his performance-focused approach, with a total of $1.15 million in 2022, which included salary, bonuses based on specific performance metrics, and other benefits. Notably, he received vested stock tied to long-term performance goals. Under his leadership, ResMed's stock has shown fluctuations, notably peaking at around $142 million in value by the end of 2021 before stabilizing. Michael's tenure is marked by a strong alignment between executive pay and company performance, showing a focus on long-term value creation. His experience in the healthcare field and strategic vision continues to drive ResMed towards greater heights in the industry.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other ResMed CEOs

R

Michael J. Farrell

CEO of ResMed

Field of Expertise

Healthcare & Life Sciences - Healthcare

Sector of Economy

Healthcare

CEO of ResMed for

5 years 10 months (Jul 2019 - Present)

Previous Experience

CEO of ResMed, Director of ResMed

Rivals

Competitors/colleagues of Michael J. Farrell

M

August J. Troendle

Founder and CEO of Medpace Holdings, Inc.

2023 Compensation

Stock

$0.00

Salary

$825.00K

Bonus

$814.42K

Other

$17.33K

Total Holdings

$1.76B

E

Mark J. Tarr

CEO of Encompass Health Corporation

2023 Compensation

Stock

$3.28M

Salary

$1.05M

Bonus

$0.00

Other

$66.92K

Total Holdings

$51.02M

H

Andrew Dudum

Founder and CEO of Hims & Hers Health

2023 Compensation

Stock

$6.54M

Salary

$625.00K

Bonus

$1.14M

Other

$167.60K

Total Holdings

$9.65M

Holdings

See how much did Michael J. Farrell make over time.

Michael J. Farrell's holdings in ResMed reflect a significant commitment to the company. He has experienced a noticeable trajectory in his asset values, especially from late 2019 to the end of 2021. For example, in December 2019, his holdings were...

Michael J. Farrell's holdings in ResMed reflect a significant commitment to the company. He has experienced a noticeable trajectory in his asset values, especially from late 2019 to the end of 2021. For example, in December 2019, his holdings were valued at approximately $47.07 million, and by December 2021, they peaked at an impressive $142.13 million. After this peak, there has been a gradual decline, with current values hovering around $67.38 million. This illustrates a typical fluctuation seen in equity markets, where initial rapid growth can give way to stabilization. Notably, these changes signify Michael’s strong belief in the company's long-term prospects, aligning with ResMed’s vision in the healthcare sector.

Mar 18, 2025

R

shares

RMD @ $220.25

Z

shares

ZBH @ $112.88

Total Stock Sold

$82.45M

RMD

$82.45M

623,967 RMD shares

What if they kept their stock?

If Michael J. Farrell didn't sell their stock, today they would have:
Extra RMD623,967 shares worth $100.27M.
This is 21.61% and $17.82M more than what they got when they sold the stock.

Charitable Transactions

RMD

55,800 shares

RMD

Recent Charitable Transactions

RMD

2,000 shares

RMD

Nov 25, 2024

Charity

RMD

1,000 shares

RMD

Nov 10, 2022

Charity

RMD

3,880 shares

RMD

Nov 30, 2021

Charity

RMD

44,250 shares

RMD

Nov 16, 2021

Charity

RMD

1,370 shares

RMD

Nov 25, 2019

Charity

RMD

3,300 shares

RMD

Nov 16, 2018

Charity

Insider Trading

See recent insider trades of Michael J. Farrell.

RMD

$1.84M

RMD at $229.20/share

Mar 7, 2025

Sale

RMD

$1.90M

RMD at $236.77/share

Feb 7, 2025

Sale

RMD

2,000 shares

RMD

Nov 25, 2024

Charity

RMD

$499.33K

RMD at $249.67/share

Nov 25, 2024

Sale

RMD

2,000 shares

RMD

Nov 25, 2024

Charity

RMD

$3.62M

RMD at $246.26/share

Nov 7, 2024

Sale

RMD

$3.41M

RMD at $231.91/share

Oct 7, 2024

Sale

RMD

$3.65M

RMD at $248.38/share

Sep 9, 2024

Sale

RMD

23,370 shares

RMD

Aug 16, 2024

Received

RMD

$3.15M

RMD at $214.25/share

Aug 7, 2024

Sale

Compensation History

See how much did Michael J. Farrell make over time.

In 2022, Michael J. Farrell's total compensation was $1.15 million, breaking down into a salary of $800,000, a bonus of $200,000 for meeting performance metrics, and $100,000 in other benefits like retirement contributions. He also vested 5,000 shares worth about $250,000 from a long-term incentive plan based on performance over three years. This structure highlights the company's philosophy of aligning executive pay with longer-term business success and shareholder interests. For context, in 2021, his total compensation was even higher at $1.85 million, pointing to a company performance-driven approach to executive pay, focusing not just on immediate results but sustainable growth.

Year

2022

Total Compensation

$1.35M

Salary

$800.00K

Board Justification

The compensation philosophy emphasizes aligning CEO pay with long-term company performance, market competitiveness, and retention of key executives.

Bonus

$200.00K

Board Justification

The bonus is based on the achievement of specific performance metrics set by the Compensation Committee for the fiscal year 2022.

Other

$100.00K

Board Justification

Other compensation includes retirement contributions, insurance premiums, and other benefits provided to the CEO in 2022.

Restricted Stock

$250.00K(5K common stock)

Board Justification

5,000 shares of common stock vested in 2022 as part of the long-term incentive plan, which is tied to performance over a three-year period.

Performance Metrics

Performance metrics include revenue growth, operating income, and total shareholder return relative to peers.

Other ResMed CEOs

Here are other CEOs of ResMed

Peter C. Farrell

Founder and Ex-CEO of ResMed

July 1989 - January 2023